

Maite Garc a-Fern andez de Barrena

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7360410/publications.pdf>

Version: 2024-02-01

78
papers

8,650
citations

182225

30
h-index

100535

70
g-index

79
all docs

79
docs citations

79
times ranked

22378
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. <i>Gut</i> , 2022, 71, 1141-1151.	6.1	32
2	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>Journal of Hepatology</i> , 2022, 77, 177-190.	1.8	11
3	Impact of <i>CYLD</i> on chromatin structure and histone methylation in malignant melanoma. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	1.8	3
4	Epigenetic remodelling in human hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 107.	3.5	21
5	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2022, 45, 724-734.	0.2	3
6	Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. <i>Cancers</i> , 2022, 14, 78.	1.7	3
7	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 2048.	1.7	5
8	New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	9
9	Dual Targeting of G9a and DNA Methyltransferase 1 for the Treatment of Experimental Cholangiocarcinoma. <i>Hepatology</i> , 2021, 73, 2380-2396.	3.6	26
10	Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. <i>Gut</i> , 2021, 70, gntjnl-2019-320205.	6.1	36
11	Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. <i>Cancers</i> , 2021, 13, 1265.	1.7	23
12	Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. <i>Oncogene</i> , 2021, 40, 4033-4049.	2.6	5
13	The TGF- β 2 Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021, 13, 3248.	1.7	37
14	The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation. <i>Nucleic Acids Research</i> , 2021, 49, 8592-8609.	6.5	2
15	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. <i>Journal of Hepatology</i> , 2021, 75, 363-376.	1.8	29
16	Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor κ B Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. <i>Hepatology</i> , 2021, 74, 2791-2807.	3.6	12
17	Chromatin dynamics during liver regeneration. <i>Seminars in Cell and Developmental Biology</i> , 2020, 97, 38-46.	2.3	10
18	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	2.9	37

#	ARTICLE	IF	CITATIONS
19	Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5500.	1.8	25
20	Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. <i>JHEP Reports</i> , 2020, 2, 100167.	2.6	51
21	Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?. <i>Cells</i> , 2020, 9, 2321.	1.8	21
22	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. <i>Cancers</i> , 2020, 12, 3748.	1.7	6
23	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. <i>Liver International</i> , 2020, 40, 1670-1685.	1.9	22
24	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. <i>Cancers</i> , 2020, 12, 1644.	1.7	38
25	GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression. <i>Biochemical Journal</i> , 2020, 477, 3131-3145.	1.7	23
26	Dual Targeting of Histone Methyltransferase G9a and DNA Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 587-603.	3.6	81
27	PS-043-Dual targeting of G9a and DNMT-methyltransferase-1 for the treatment of experimental cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 70, e27-e28.	1.8	1
28	THU-468-SLU7 controls genome integrity: New role of truncated SRSF3 proteins. <i>Journal of Hepatology</i> , 2019, 70, e365-e366.	1.8	0
29	THU-064-Identification of new epigenetic targets in hepatic fibrosis. <i>Journal of Hepatology</i> , 2019, 70, e188.	1.8	0
30	Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins. <i>Nucleic Acids Research</i> , 2019, 47, 3450-3466.	6.5	53
31	Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2507.	1.8	45
32	The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. <i>Hepatology</i> , 2019, 69, 1632-1647.	3.6	42
33	Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1326-1334.	1.8	34
34	MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. <i>Hepatology</i> , 2018, 67, 1420-1440.	3.6	72
35	Fibroblast growth factors 19 and 21 in acute liver damage. <i>Annals of Translational Medicine</i> , 2018, 6, 257-257.	0.7	11
36	Novel role of amphiregulin in bile acids metabolism and protection from cholestatic liver injury. <i>Journal of Hepatology</i> , 2018, 68, S74.	1.8	0

#	ARTICLE	IF	CITATIONS
37	New evidence supporting the biliary bicarbonate umbrella theory. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 126-128.	0.7	3
38	IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis. <i>Cancer Research</i> , 2017, 77, 320-329.	0.4	29
39	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 72-83.	1.8	81
40	Novel lncRNA T-UCR as a potential downstream driver of the Wnt/ β -catenin pathway in hepatobiliary carcinogenesis. <i>Gut</i> , 2017, 66, 1177-1178.	6.1	19
41	Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. <i>Gut</i> , 2017, 66, 1818-1828.	6.1	118
42	Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis. <i>Digestive Diseases</i> , 2017, 35, 158-165.	0.8	35
43	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. <i>Nature Communications</i> , 2017, 8, 15424.	5.8	109
44	Development of novel epigenetic inhibitors for the treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, S76-S77.	1.8	0
45	Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. <i>Cell Death and Disease</i> , 2017, 8, e3083-e3083.	2.7	17
46	New molecular interactions of c-Myc in cholangiocarcinoma may open new therapeutic opportunities. <i>Hepatology</i> , 2016, 64, 336-339.	3.6	3
47	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2016, 22, 4259-4270.	3.2	44
48	SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumour Suppressor in Cholangiocarcinoma. <i>Journal of Hepatology</i> , 2016, 64, S569-S570.	1.8	1
49	Overexpression of Mirna-506 in Human Cholangiocytes Causes Primary Biliary Cholangitis-Like Features including Mitochondrial Dysfunction and Increased Sensitivity to Apoptosis. <i>Journal of Hepatology</i> , 2016, 64, S639-S640.	1.8	1
50	Development of a New Hepatoprotective and Proregenerative Molecule Based on Fibroblast Growth Factor 15/19. <i>Journal of Hepatology</i> , 2016, 64, S184.	1.8	2
51	Nuclear Factor of Activated T Cells-dependent Down-regulation of the Transcription Factor Glioma-associated Protein 1 (GLI1) Underlies the Growth Inhibitory Properties of Arachidonic Acid. <i>Journal of Biological Chemistry</i> , 2016, 291, 1933-1947.	1.6	17
52	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
53	Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression. <i>Oncogene</i> , 2016, 35, 4719-4729.	2.6	27
54	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/CXCL12 chemokine receptor 4 axis. <i>Hepatology</i> , 2015, 62, 166-178.	3.6	61

#	ARTICLE	IF	CITATIONS
55	Ileal <scp>FGF</scp>15 contributes to fibrosis-associated hepatocellular carcinoma development. International Journal of Cancer, 2015, 136, 2469-2475.	2.3	79
56	O096 : Matrix metalloproteinase-10 contributes to hepatocellular carcinoma development in a novel crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis. Journal of Hepatology, 2015, 62, S242.	1.8	0
57	The Transcription Factor GLI1 Interacts with SMAD Proteins to Modulate Transforming Growth Factor β -Induced Gene Expression in a p300/CREB-binding Protein-associated Factor (PCAF)-dependent Manner. Journal of Biological Chemistry, 2014, 289, 15495-15506.	1.6	52
58	Discovering and targeting the epigenetic pathways to treat muscle loss. Current Opinion in Supportive and Palliative Care, 2014, 8, 319-320.	0.5	1
59	Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1. Molecular Oncology, 2014, 8, 912-926.	2.1	33
60	Galectin-1 Drives Pancreatic Carcinogenesis through Stroma Remodeling and Hedgehog Signaling Activation. Cancer Research, 2014, 74, 3512-3524.	0.4	100
61	Inactivation of the Transcription Factor GLI1 Accelerates Pancreatic Cancer Progression. Journal of Biological Chemistry, 2014, 289, 16516-16525.	1.6	22
62	Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver International, 2014, 34, e257-70.	1.9	43
63	The Transcription Factor GLI1 Modulates the Inflammatory Response during Pancreatic Tissue Remodeling. Journal of Biological Chemistry, 2014, 289, 27727-27743.	1.6	43
64	O97 GUT-DERIVED FGF15 PLAYS A CENTRAL ROLE IN FIBROSIS-ASSOCIATED HEPATOCARCINOGENESIS. Journal of Hepatology, 2014, 60, S40.	1.8	0
65	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	6.1	55
66	Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2014, 25, 735-747.	7.7	1,616
67	Epigenetic control of KRAS-induced transformation by GLI transcription factors. Pancreatology, 2013, 13, e25.	0.5	0
68	300 IDENTIFICATION OF MATRIX METALLOPROTEASE 10 (MMP10) AS A KEY NEW MEDIATOR OF THE REGENERATIVE RESPONSE OF THE LIVER. Journal of Hepatology, 2013, 58, S126.	1.8	0
69	Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut, 2013, 62, 899-910.	6.1	163
70	Activation of the Transcription Factor GLI1 by WNT Signaling Underlies the Role of SULFATASE 2 as a Regulator of Tissue Regeneration. Journal of Biological Chemistry, 2013, 288, 21389-21398.	1.6	31
71	GLI1 Inhibition Promotes Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells. Cancer Research, 2012, 72, 88-99.	0.4	60
72	GLI1 Modulates EMT in Pancreatic Cancer's Response. Cancer Research, 2012, 72, 3704-3705.	0.4	1

#	ARTICLE	IF	CITATIONS
73	MicroRNAs in biliary diseases. <i>World Journal of Gastroenterology</i> , 2012, 18, 6189.	1.4	30
74	Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. <i>Journal of Hepatology</i> , 2012, 56, 367-373.	1.8	43
75	Novel AKT1-GLI3-VMP1 Pathway Mediates KRAS Oncogene-induced Autophagy in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 25325-25334.	1.6	76
76	The Transcription Factor GLI1 Mediates TGF β 21 Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism. <i>PLoS ONE</i> , 2012, 7, e49581.	1.1	68
77	Disposable sensors for rapid screening of mutated genes. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 1385-1393.	1.9	14
78	Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr2 Δ/Δ Mice. <i>PLoS ONE</i> , 2010, 5, e15690.	1.1	23